Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Merck pays $588M for bispecific to defend Keytruda’s kingdom
The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.
Nick Paul Taylor
Nov 14, 2024 7:45am
BioNTech pays $800M to take control of potential Keytruda killer
Nov 13, 2024 6:45am
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 10:00am
Crescent inks GlycoMimetics merger, securing listing and $200M
Oct 29, 2024 10:20am
Shattuck axes CD47 program, cuts 40% of staff over weak data
Oct 1, 2024 8:22am
AstraZeneca extends AI immuno-oncology R&D pact with Immunai
Sep 26, 2024 9:00am
